How to Deal with the Temperature Instability that is Unavoidable During Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?

Since cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been accepted worldwide as a promising treatment model for end-stage cancer patients with peritoneal involvement, the major concern of the procedure emerging from the experience gained from wide series seems to be ‘thermoregulation'. Consecutive procedures starting with extensive abdominal exploration and CRS, concerning the large area of surgical exposure for a long period of time and loss of ascites outside, will absolutely result in hypothermia.